Top Markets
#1 GoPlus Security GoPlus Security +38.24%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.88%
#3 Tutorial Tutorial +18.60%
#4 Status Status +14.45%
#5 Pons Pons +14.35%
#6 Wrapped NXM Wrapped NXM +14.12%
#7 Verus Coin Verus Coin +12.97%
#8 SkyAI SkyAI +10.81%
#9 o1.exchange o1.exchange +10.06%
#10 DMT-NAT DMT-NAT +8.92%
Coin of the day
GoPlus Security GoPlus Security
Configurações
Idioma
PORTUGUêS
Moeda
USD
Tema
Incannex Healthcare Limited Incannex Healthcare Limited

Incannex Healthcare Limited

IHL
Classificação em ações #33838
Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited,... Established in Melbourne, Australia, in 2001, Incannex Healthcare Limited, which operated as Impression Healthcare Limited until its rebranding in June 2020, is dedicated to the research, development, and commercialization of pharmaceutical products and therapies derived from medicinal cannabinoids and psychedelics. Its offerings include a trio of ultrapure cannabinoid compounds: APIRx-1801 (tetrahydrocannabinol), APIRx-1802 (CBD), and APIRx-1803 (cannabigerol). The company's clinical pipeline features IHL-42X, which has concluded Phase IIa trials for obstructive sleep apnea, and Psi-GAD, currently in Phase IIa development for generalized anxiety disorder. Other compounds having successfully advanced through Phase IIa clinical trials include CanChew Plus for irritable bowel syndrome, APIRx-1601 for vitiligo, APIRx-1602 for psoriasis, and APIRx-1603 for atopic dermatitis. Additionally, MedChew Dronabinol has completed Phase Ia trials for chemotherapy-induced nausea and vomiting. Its pre-clinical portfolio is extensive, including IHL-675A, which has completed studies for inflammatory lung disease, rheumatoid arthritis, and inflammatory bowel disease, alongside IHL-216A for traumatic brain injury/concussion. A broad array of further candidates are actively undergoing pre-clinical investigation, such as MedChew 1401 for pain and spasticity in multiple sclerosis, MedChew GB for post-herpetic neuralgia, MedChew-1502 for Parkinson's disease, MedChew-1503 for dementia, MedChew RL for restless legs syndrome, APIRx 1505 Flotex for Crohn's disease, CanChew RX and SuppoCan (Suppository) for inflammatory bowel disease, CheWell for cannabis addiction, CanQuit for tobacco smoking cessation, CanQuit O for opioid addiction, APIRx-1701 for glaucoma, and APIRx-1702 for dry eye syndrome.
Preço da ação
$0.0270762
Última sincronização: 2023-11-30
Valor de mercado
$6.78M
Variação (1 dia)
-0.66%
Variação (1 ano)
0.00%
País
AU
Negociar Incannex Healthcare Limited (IHL)

Categoria

Healthcare
Histórico de dividendos de Incannex Healthcare Limited (IHL)
Incannex Healthcare Limited (símbolo da ação: IHL) realizou um total de 0 pagamentos de dividendos.
A soma de todos os dividendos (ajustada para desdobramentos de ações) é: 0.00
Rendimento de dividendos (TTM): 0
Pagamentos de dividendos de Incannex Healthcare Limited (IHL) de 2026 a 2026
Pagamentos anuais de dividendos
Ano Dividendo (ajustado para desdobramentos) Alterar
Não há dados suficientes para as datas fornecidas.
Lista de todos os pagamentos de dividendos
Ano Dividendo Alterar
Não há dados suficientes para as datas fornecidas.
Dividendos de empresas semelhantes ou concorrentes
Empresa Número de pagamentos de dividendos País
MERCK Kommanditgesellschaft auf Aktien MERCK Kommanditgesellschaft auf Aktien
MERCK Kommanditgesellschaft auf Aktien
MER.SW
0.00%
DE
Merck KGaA Merck KGaA
Merck KGaA
MRK.DE
0.00%
DE
Takeda Pharmaceutical Company Limited Takeda Pharmaceutical Company Limited
Takeda Pharmaceutical Company Limited
4502.T
0.00%
JP
Galderma Group AG Galderma Group AG
Galderma Group AG
GALD.SW
0.00%
CH
Sun Pharmaceutical Industries Limited Sun Pharmaceutical Industries Limited
Sun Pharmaceutical Industries Limited
SUNPHARMA.NS
38.00%
IN